Open Beta
TREN
MetriLume
TREN

US marketsAUTL

SEC-sourced researchBeta

AUTL

Autolus Therapeutics plc

Company comparison ↗

Data passport

CIK
0001730463
Exchange
Nasdaq
Business activity
Biological Products, (No Diagnostic Substances) · SIC 2836
Financial inputs
6/6
Filing date
Sep 22, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 10,120,000.0000 USD; December 2025: 75,388,000.0000 USD75.4M USD0 USD0December 2024December 2025
AUTL · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202410,120,000.0000Mar 27, 2026
December 202575,388,000.0000Mar 27, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202575,388,000.0000-287,528,000.0000-283,568,000.0000589,068,000.0000410,939,000.0000Mar 27, 2026
December 202410,120,000.0000-220,662,000.0000-206,271,000.0000782,725,000.0000355,400,000.0000Mar 27, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

46/100
Profitability0
Growth100
Balance sheet30
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$75.39MJan 1, 2025 – Dec 31, 2025Mar 27, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$10.12MJan 1, 2024 – Dec 31, 2024Mar 27, 202610-K
Net incomeNetIncomeLoss-$287.53MJan 1, 2025 – Dec 31, 2025Mar 27, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$283.57MJan 1, 2025 – Dec 31, 2025Mar 27, 202610-K
Total assetsAssets$589.07MDec 31, 2025Mar 27, 202610-K
Total liabilitiesLiabilities$410.94MDec 31, 2025Mar 27, 202610-K

New filings

Explore methodology ↗